ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors Yahoo Finance
FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash Fierce Pharma
RNA Test Shows Promise for Guiding Bladder Cancer Treatment Medscape
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC Urology Times
ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion Yahoo Finance
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer Yahoo Finance
IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline Yahoo Finance
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease Yahoo Finance
Bladder cancer mistaken for UTI, perimenopause in women ABC News & Headlines – Australian Broadcasting Corporation
Bladder cancer detected up to five years before diagnosis—thanks to AI Medical Xpress
OncLive Weekly News Quiz (10/16/2026): Did You Miss Crucial Bladder, Neuroendocrine, Pancreatic, and Liver Cancer Updates? OncLive
Enrique Grande: Rethinking Research Priorities Across Prostate, Kidney and Bladder Cancer Oncodaily
Bladder Cancer: FDA Expands Anktiva Without a New Trial PharmTech.com
Anktiva for Papillary Bladder Cancer: What Patients Should Know Cure Today
FDA Expands Anktiva Approval in Bladder Cancer Medscape
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer The American Journal of Managed Care
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path Yahoo Finance
Bladder Cancer Study Challenges WHO’s 5% Rule for Grading Mixed Tumors Bioengineer.org
Urine cell-free RNA for bladder cancer detection and treatment response prediction Nature
Urine test may improve bladder cancer diagnosis and guide treatment decisions Stanford Medicine
FDA Expands IL-15 Agonist Approval to Papillary-Only NMIBC Oncology News Central
Recon: ImmunityBio’s Anktiva clears FDA expansion in bladder cancer; “Gross contamination” found at Chinese site manufacturing GLP-1 components RAPS
ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion Pharmaceutical Technology
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer Cure Today
Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution Urology Times
What Comes Next? Treatment Sequencing in Advanced Urothelial Carcinoma Oncodaily
Timothy Clinton, MD, reviews bladder cancer data from 2026 AUA Northeastern Section Meeting Urology Times
FDA Approval Expands Anktiva to BCG-Unresponsive Papillary Bladder Cancer Pharmacy Times
FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer Mega Doctor News
Billionaire Patrick Soon-Shiong wins wider FDA approval for bladder cancer drug Billionaires.Africa
FDA broadens Anktiva's bladder cancer label months ahead of schedule FirstWord Pharma
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC CancerNetwork
Some bladder cancer patients had complete responses lasting beyond 53 months Stock Titan
FDA Expands Anktiva Approval to Papillary-Only Bladder Cancer That Resists BCG, Giving Patients a Nonsurgical Option Medical Daily
FDA Expands Nogapendekin Alfa Inbakicept Indication in BCG-Unresponsive NMIBC Targeted Oncology
Dillon Cockrell: ESMO26 is Approaching With Several Key GU Studies Being Presented Next Week Oncodaily
Three-year data show durable responses with mitomycin intravesical solution Urology Times
Armine K. Smith, MD, on sexual health counseling before cystectomy Urology Times
FDA Approves First Treatment for Certain Patients With Unresponsive Bladder Cancer The Well News
ImmunityBio reports long-term bladder cancer treatment data By Investing.com Investing.com India